Resource Type

Journal Article 834

Conference Videos 48

Conference Information 3

Year

2024 4

2023 71

2022 97

2021 131

2020 81

2019 64

2018 53

2017 53

2016 27

2015 34

2014 27

2013 38

2012 29

2011 30

2010 18

2009 34

2008 15

2007 27

2006 4

2005 2

open ︾

Keywords

COVID-19 66

SARS-CoV-2 27

fuel cell 13

immunotherapy 12

cancer 10

targeted therapy 8

Coronavirus disease 2019 7

hepatocellular carcinoma 7

solar cell 6

hematopoietic stem cell transplantation 5

hydrogen energy 5

lung cancer 5

stem cell 5

cadmium (Cd) 4

cell proliferation 4

control 4

coronavirus disease 2019 (COVID-19) 4

microbial fuel cell 4

solid oxide fuel cell 4

open ︾

Search scope:

排序： Display mode:

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation Article

Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang

Engineering 2019, Volume 5, Issue 1,   Pages 150-155 doi: 10.1016/j.eng.2018.12.006

Abstract: transplantation (allo-HSCT) for B cell acute lymphoblastic leukemia (B-ALL).Donor lymphoblastic infusion (DLI) is the main established approach to treat B-ALL with MRD after allo-HSCTAlthough donor-derived cluster of differentiation (CD)19-directed chimeric antigen receptor-modified(CAR) T cells (CART19s) can potentially cure leukemia, the efficiency and safety of infusions with theseDonor-derived CAR T cell infusions seem to be an effective and safe intervention for patients with MRD

Keywords： Donor-derived CD19-targeted T cell infusion     Hematopoietic stem cell transplantation     B cell acute lymphoblastic    

HTML PDF Collect

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecificantibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 139-149 doi: 10.1007/s11684-021-0835-8

Abstract: The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients withBlinatumomab and A-319 are CD3/CD19 bispecific antibodies with different molecular sizes and structures, and A-2019 is a novel CD3/CD19/CD20 trispecific antibody with an additional anti-CD20 function.positive T cells, enhancing T-cell function, mediating B-cell depletion, and eventually inhibiting tumorin cells missing CD19, suggesting its potential function against CD19 weak or negative CD20 positive

Keywords： B-cell acute lymphoblastic leukemia     bispecific antibody     trispecific antibody     CD19     CD20    

HTML PDF Collect

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Frontiers of Medicine doi: 10.1007/s11684-023-1010-1

Abstract: Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Keywords： exosomes induce activation     impair function CD19     exosomal CD19 antigen    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellA multi-center phase I/II trial of anti-CD19 CD28z CAR-T (FKC876, ChiCTR1800019661) was conducted.cells, leading to CAR-T cell therapy failure and disease progression in DLBCL.Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansion

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellcells transduced with CBM.CD19 CAR, a second-generation anti-CD19 CAR bearing 4-1BB costimulatory moleculeTen heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatmentThe overall response rate was 20% and 50% at 4 and 12 weeks after the infusion of C-CAR011, respectively, and the disease control rate was 60% at 12 weeks after infusion.

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donorlymphocyte infusion

Frontiers of Medicine 2021, Volume 15, Issue 5,   Pages 728-739 doi: 10.1007/s11684-021-0833-x

Abstract: Relapse is the main problem after allogeneic hematopoietic stem cell transplantation (allo-HSCT).efficacy of HSCT2 in patients with relapsed/refractory acute leukemia (AL) post-chemotherapy plus modified donorlymphocyte infusion (post-Chemo+m-DLI) after the first allo-HSCT (HSCT1).

Keywords： second hematopoietic stem cell transplantation     acute leukemia     relapse     chemotherapy     modified donorlymphocyte infusion    

HTML PDF Collect

leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donorlymphocyte infusion after allogeneic hematopoietic stem cell transplantation

Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang

Frontiers of Medicine 2019, Volume 13, Issue 2,   Pages 238-249 doi: 10.1007/s11684-017-0599-3

Abstract: was investigated in patients with unsatisfactory response to minimal residual disease (MRD)-directed donorlymphocyte infusion (DLI) ( =24).DLI and could be a potential salvage treatment for these patients after allogeneic hematopoietic stem cell

Keywords： interferon-α     hematopoietic stem cell transplantation     minimal residual disease     donor lymphocyte infusion    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallypatient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cellCAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor Tcell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (CAR-T) cell immunotherapy for relapsed or refractory non-Hodgkin lymphoma (r/r NHL) have not been welloverall survival (OS), and progression-free survival (PFS) in patients with r/r NHL treated with anti-CD19CAR-T cell therapy.Thus, anti-CD19 CAR-T cell therapy may improve the prognosis of patients with BM infiltration.

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Clinical significance of CD34+CD117dim/CD34+CD117bri myeloblast-associatedgene expression in t(8;21) acute myeloid leukemia

Xueping Li, Yuting Dai, Bing Chen, Jinyan Huang, Saijuan Chen, Lu Jiang

Frontiers of Medicine 2021, Volume 15, Issue 4,   Pages 608-620 doi: 10.1007/s11684-021-0836-7

Abstract: Two leukemic myeloblast populations (CD34 CD117 and CD34 CD117 ) were previously identified in t(8;21) AML, and CD34 CD117 cell proportion was determined as an independent factor for this disease outcomeHere, we examined the impact of CD34 CD117 /CD34 CD117 myeloblast-associated gene expression on t(8;In this study, 85 patients with t(8;21) AML were enrolled.Univariate analysis revealed that CD19, CD34 CD117 proportion, mutation, minimal residual disease

Keywords： t(8     21)(q22     q22) AML     CD34+CD117dim/ CD34+CD117bri cell population    

HTML PDF Collect

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 815-826 doi: 10.1007/s11684-021-0891-0

Abstract: Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL)

Keywords： B-cell lymphoma     oral drug     targeted therapy     immunotherapy     COVID-19 pandemic    

HTML PDF Collect

Engineered T Cell Therapies from a Drug Development Viewpoint Review

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Engineering 2019, Volume 5, Issue 1,   Pages 140-149 doi: 10.1016/j.eng.2018.11.010

Abstract: For example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowingAnti-CD19 chimeric antigen receptor T cells (CART19) have demonstrated a remarkable degree of clinicalThe process of developing CART19 essentially follows the conventional “one gene, one drug, onedisease” paradigm derived from Paul Ehrlich’s “magic bullet” concept.We believe that the success of CART19 will lead to the development of other engineered T cell therapies

Keywords： Engineered T cell therapies     Chimeric antigen receptor     Drug development process     Biomarkers     CAR19     CART19    

HTML PDF Collect

An 84-month observational study of the changes in CD4 T-lymphocyte cell count of 110 HIV/AIDS patients

Jian Wang,Biyan Liang,Xiaoping Zhang,Liran Xu,Xin Deng,Xiuhui Li,Lu Fang,Xinghua Tan,Yuxiang Mao,Guoliang Zhang,Yuguang Wang

Frontiers of Medicine 2014, Volume 8, Issue 3,   Pages 362-367 doi: 10.1007/s11684-014-0363-x

Abstract: T-lymphocyte cell count of 110 cases with human immunodeficiency virus (HIV)/acquired immunodeficiencyInformation of 110 HIV/AIDS patients from 19 provinces and cities treated with TCM from 2004 to 2013For CD4 count of≤200 cells/mm3, the mean CD4 count changes were 21 and 28 cells/mmFor CD4 count of 201–350 cells/mm3, the mean CD4 count changes were 6 and 25 cells/mmFor CD4 count of 351–500 cells/mm3, the mean CD4 count changes were -13 and -7 cells

Keywords： AIDS     HIV     CD4     traditional Chinese medicine     linear models    

HTML PDF Collect

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 689-700 doi: 10.1007/s11684-020-0759-8

Abstract: and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cellprecursor, immature T-cell, -rearranged, Ph-positive and -positive ALL, that may respond to BCL-2There are other fusions or mutations that may serve as putative targets, but effective targeted therapycell therapy for B-ALL, and daratumumab and nelarabine for T-ALL.With the expanding therapeutic armamentarium, we should start focus on rational combinations of targeted

Keywords： acute lymphoblastic leukemia     molecular therapeutics     targeted therapy     tyrosine kinase inhibitors     immunotherapy     CAR T-cell therapy    

HTML PDF Collect

disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell

Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang

Frontiers of Medicine 2019, Volume 13, Issue 3,   Pages 354-364 doi: 10.1007/s11684-018-0665-5

Abstract: including interferon- (IFN- ) treatment and chemotherapy plus granulocyte colony-stimulating factor-primed donorleukocyte infusion (chemo-DLI), was investigated in patients with high-risk myelodysplastic syndrome(MDS) who were MRD-positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT).High-risk MDS patients who received non-T-cell-depleted allo-HSCT at the Peking University Institute

Keywords： donor leukocyte infusion     hematopoietic stem cell transplantation     interferon-   

HTML PDF Collect

Title Author Date Type Operation

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal ResidualDisease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation

Yifei Cheng,Yuhong Chen,Chenhua Yan,Yu Wang,Xiangyu Zhao,Yao Chen,Wei Han,Lanping Xu,Xiaohui Zhang,Kaiyan Liu,Shasha Wang,Lungji Chang,Lei Xiao,Xiaojun Huang

Journal Article

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecificantibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic

Journal Article

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donorlymphocyte infusion

Journal Article

leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donorlymphocyte infusion after allogeneic hematopoietic stem cell transplantation

Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimeric antigen receptor Tcell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Clinical significance of CD34+CD117dim/CD34+CD117bri myeloblast-associatedgene expression in t(8;21) acute myeloid leukemia

Xueping Li, Yuting Dai, Bing Chen, Jinyan Huang, Saijuan Chen, Lu Jiang

Journal Article

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Journal Article

Engineered T Cell Therapies from a Drug Development Viewpoint

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Journal Article

An 84-month observational study of the changes in CD4 T-lymphocyte cell count of 110 HIV/AIDS patients

Jian Wang,Biyan Liang,Xiaoping Zhang,Liran Xu,Xin Deng,Xiuhui Li,Lu Fang,Xinghua Tan,Yuxiang Mao,Guoliang Zhang,Yuguang Wang

Journal Article

Precision medicine in acute lymphoblastic leukemia

Ching-Hon Pui

Journal Article

disease-directed immunotherapy for high-risk myelodysplastic syndrome after allogeneic hematopoietic stem cell

Xiaodong Mo, Xiaohui Zhang, Lanping Xu, Yu Wang, Chenhua Yan, Huan Chen, Yuhong Chen, Wei Han, Fengrong Wang, Jingzhi Wang, Kaiyan Liu, Xiaojun Huang

Journal Article